Aequus Pharmaceuticals AI Stock Analysis
Want to see TSE:AQS full AI Analyst Report?
Aequus Pharmaceuticals (AQS) AI Stock Analysis
Aequus Pharmaceuticals
(TSXV:AQS)
Low score driven by weak financials (high risk from negative equity and cash burn) and poor technicals/valuation; revenue growth offers minor offset but viability concerns dominate.
Aequus Pharmaceuticals (AQS) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 663.17K
- Dividend Yield
- ―
- Average Volume (3M)
- 10.00K
- Price to Earnings (P/E)
- 3.1
- Beta (1Y)
- -8.23
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Canada
- Employees
- 12
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Aequus Pharmaceuticals Business Overview & Revenue Model
Company Description
Aequus Pharmaceuticals Inc. is a specialized Canadian pharmaceutical company dedicated to advancing and commercializing therapeutic solutions. Its core operations span critical areas such as neurology, ophthalmology, and transplantation. The company...
How the Company Makes Money
Aequus makes money primarily by commercializing pharmaceutical products that it has acquired or in-licensed, generating revenue from product sales and/or commercialization-related payments under its licensing agreements. Key revenue streams can inclu...
Aequus Pharmaceuticals Financial Statement Overview
Summary
Weak overall financials with sharp revenue growth offset by deep losses (net margin -373%), negative equity (-$6.5M), high debt-to-equity (-1.02), and ongoing cash burn (-$1.7M operating cash flow).
Income Statement
35NegativeBalance Sheet
15Very NegativeCash Flow
25Negative| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 815.03K | 584.24K | 254.90K | 1.38M | 2.71M | 2.59M |
| Gross Profit | 433.33K | 199.97K | 143.66K | 1.15M | 2.69M | 2.59M |
| EBITDA | -1.13M | -1.79M | -2.68M | -2.87M | -1.23M | -314.80K |
| Net Income | -1.64M | -2.18M | -2.96M | -3.21M | -1.81M | -1.05M |
Balance Sheet | ||||||
| Total Assets | 236.02K | 800.28K | 1.09M | 1.69M | 4.35M | 3.13M |
| Cash, Cash Equivalents and Short-Term Investments | 35.08K | 50.24K | 170.20K | 294.67K | 2.39M | 1.72M |
| Total Debt | 6.64M | 6.61M | 5.06M | 782.92K | 2.18M | 2.32M |
| Total Liabilities | 7.51M | 7.26M | 5.38M | 3.07M | 2.56M | 2.56M |
| Stockholders Equity | -7.27M | -6.45M | -4.29M | -1.38M | 1.79M | 573.95K |
Cash Flow | ||||||
| Free Cash Flow | -443.32K | -1.66M | -2.29M | -1.95M | -1.18M | -817.23K |
| Operating Cash Flow | -443.32K | -1.66M | -2.29M | -1.95M | -1.17M | -804.91K |
| Investing Cash Flow | 44.85K | 44.85K | 0 | 0 | -507.96K | -12.32K |
| Financing Cash Flow | 389.47K | 1.49M | 2.21M | -189.19K | 2.40M | 2.05M |
Aequus Pharmaceuticals Peers Comparison
Overall Rating
TSE:MDP63Neutral
TSE:MPH49Neutral
TSE:TGIF45Neutral
TSE:PHRX41Neutral
TSE:AQS30Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 63Neutral | CAD 179.44M | -96.96 | -2.49% | ― | 2.62% | -337.50% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | CAD 38.61M | -5.40 | -62.34% | ― | 21.43% | -115.16% | |
| 45Neutral | CAD 2.60M | 6.25 | -11.60% | ― | -4.90% | ― | |
| 41Neutral | CAD 671.07K | -0.93 | 37.95% | ― | ― | -62.50% | |
| 30Underperform | CAD 663.17K | 3.13 | -2.92% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:AQS | Aequus Pharmaceuticals | 0.01 | 0.00 | 0.00% | |
| TSE:PHRX | Pharmadrug Inc. | 0.01 | -0.00 | -33.33% | |
| TSE:MPH | Medicure Inc | 3.83 | 2.59 | 208.87% | |
| TSE:MDP | Medexus Pharmaceuticals | 5.59 | 2.88 | 106.27% | |
| TSE:TGIF | 1933 Industries, Inc. | 0.01 | 0.00 | 0.00% |
Aequus Pharmaceuticals Corporate Events
Aequus Pharmaceuticals Clarifies Shareholder Meeting Details Amid Regulatory Disclosures
NeutralAequus Pharmaceuticals has provided additional information regarding its upcoming annual general and special meeting of shareholders, scheduled for November 21, 2025. The company clarified details about a potential share consolidation, stating it wil...
Aequus Pharmaceuticals Updates Shareholders on Key Meeting Details
NeutralAequus Pharmaceuticals has provided additional information regarding its upcoming annual general and special meeting of shareholders, as requested by the Ontario Securities Commission. The company clarified details about a potential share consolidati...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Dec 30, 2025
